Larvol Delta - A2-Biotherapeuticsannounced-the-presentation-of-early-efcacy-and-safety-data-from-the-EVEREST2-study-NCT06051695-during-the-IASLC-2025-World-Conference-on-Lung-Cancer

A2B694 - A2 Biotherap

https://www.businesswire.com/news/home/20250904676127/en/A2-Biotherapeutics-Presents-Data-from-Ongoing-Phase-12-EVEREST-2-Study-During-the-International-Association-for-the-Study-of-Lung-Cancer-2025-World-Conference-on-Lung-Cancer

Sep 8, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next